PRESS RELEASE DUBLIN.

Logo-ttp://photos.prnewswire.com/p. The acquisition of Auden Mckenzie makesActavisthe number one provider of generic pharmaceuticals in theUKand gives the Company the number three position in the supply ofUKpharmaceuticals. The acquisition of Auden Mckenzie is usually a strategic mixture that makesActavisthe number 1 generic firm in theUKand aligns with this strategy to establish a leading position in every of our marketplaces, franchises and therapeutic groups, saidBrent Saunders, President and CEO of Actavis. Auden Mckenzie's knowledge in the advancement and commercialization of quality value, technically demanding formulations as well as specialized and specific niche market opportunities is complementary to and expandsActavis'UKbusiness concentrate, saidRobert Stewart, Executive Vice President Actavis, and President, Global and Generics Operations.In 2008, a complete of 68.4 percent of the episodes of invasive pneumococcal disease among individuals 65 years or older were caused by PCV13 serotypes .38 Through the scholarly study period, in 2013, this %age decreased to 42.3 percent caused by PCV13 serotypes . In addition, the analysis was not designed to show efficacy among patients in whom an immunosuppressing condition developed after enrollment. Such occasions that happened after randomization were excluded from the per-protocol analysis.